Αρχική World News EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib World News EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Από Ogkologos - 22 Μαΐου, 2026 379 0 Facebook Twitter Google+ Pinterest WhatsApp Palbociclib Viatris is a generic of Ibrance which has been authorised in the EU since 2016 Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR A Better Biomarker for Cancer Immunotherapy? 3 Νοεμβρίου, 2023 A tribute to Dame Valerie Beral 13 Οκτωβρίου, 2022 Makeup Artist Gives Breast Cancer Survivors Free Makeovers 6 Ιανουαρίου, 2021 EMA Recommends Extension of Indications for Blinatumomab 9 Ιουνίου, 2021 Φόρτωση περισσοτέρων HOT NEWS Breathing for Stress Reduction FDA Approves Zolbetuximab-clzb with Chemotherapy for Gastric or Gastro-Oesophageal Junction Adenocarcinoma Colonoscopy after Positive FIT Test Cuts Risk of Colorectal Cancer Death FDA Approves Teclistamab in Combination with Daratumumab Hyaluronidase-fihj for Relapsed or...